{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:00:11Z","timestamp":1789585211800,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective and results description<\/jats:title>\n                <jats:p>The study objective was to investigate the potential of quantitative measures of pulmonary inflammation by [18\u00a0F]Fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) as a surrogate marker of inflammation in COPD. Patients treated with anti-inflammatory Liraglutide were compared to placebo and correlated with inflammatory markers. 27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET\/CT before and after treatment. Two raters independently segmented the lungs from CT images and measured activity in whole lung, mean standard uptake values (SUVmean) corrected for lean-body-mass in the phase-matched PET images of the whole segmented lung volume, and total lesion glycolysis (TLG; SUVmean multiplied by volume). Inter-rater reliability was analyzed with Bland-Altman analysis and correlation plots. We found no differences in metabolic activity in the lungs between the two groups as a surrogate of pulmonary inflammation, and no changes in inflammation markers. The purpose of the research and brief summary of main findings. The degree of and changes in pulmonary inflammation in chronic obstructive pulmonary disease (COPD) may be difficult to ascertain. Measuring metabolic activity as a surrogate marker of inflammation by FDG-PET\/CT may be useful, but data on its use in COPD including reproducibility is still limited, especially with respiration-gated technique, which should improve quantification in the lungs. We assessed several quantitative measures of metabolic activity and correlated them with inflammation markers, and we assessed reproducibility of the methods. We found no differences in metabolic activity between the two groups (before and after 40 weeks treatment with Liraglutide vs. placebo). Bland-Altman analysis showed good agreement between the two raters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The study was conducted between February 2018 and March 2020 at the Department of Pulmonary Diseases at Hospital South West Jutland and Lillebaelt Hospital, Denmark, and registered from March 2018 at clinicaltrials.gov with trial registration number NCT03466021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-024-06820-w","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:02:56Z","timestamp":1718877776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FDG-PET\/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-9969","authenticated-orcid":false,"given":"Ayse Dudu Altintas","family":"Dogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Quist","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Tranborg","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Bogh","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"Bladbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"6","key":"6820_CR1","first-page":"255","volume":"9","author":"BT Kung","year":"2019","unstructured":"Kung BT, Seraj SM, Zadeh MZ, Rojulpote C, Kothekar E, Ayubcha C, et al. An update on the role of (18)F-FDG-PET\/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. 2019;9(6):255\u201373.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"6820_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1513\/pats.200707-096ET","volume":"5","author":"JA Falk","year":"2008","unstructured":"Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):506\u201312.","journal-title":"Proc Am Thorac Soc"},{"issue":"12","key":"6820_CR3","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1210\/en.2013-1666","volume":"154","author":"NE Viby","year":"2013","unstructured":"Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503\u201311.","journal-title":"Endocrinology"},{"issue":"1","key":"6820_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","volume":"15","author":"M Yu","year":"2023","unstructured":"Yu M, Wang R, Pei L, Zhang X, Wei J, Wen Y, et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15(1):164.","journal-title":"Diabetol Metab Syndr"},{"key":"6820_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/COPD.S350133","volume":"17","author":"AD Altintas Dogan","year":"2022","unstructured":"Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB. Respiratory effects of treatment with a Glucagon-Like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022;17:405\u201314.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"6820_CR6","doi-asserted-by":"crossref","unstructured":"Vass L, Fisk M, Cheriyan J, Mohan D, Forman J, Oseni A et al. Quantitative (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Res. 2021;7(3).","DOI":"10.1183\/23120541.00699-2020"},{"issue":"1","key":"6820_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/MNM.0000000000000212","volume":"36","author":"GG Choi","year":"2015","unstructured":"Choi GG, Han Y, Weston B, Ciftci E, Werner TJ, Torigian D, et al. Metabolic effects of pulmonary obstruction on myocardial functioning: a pilot study using multiple time-point 18F-FDG-PET imaging. Nucl Med Commun. 2015;36(1):78\u201383.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"6820_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13550-017-0291-2","volume":"7","author":"C Coello","year":"2017","unstructured":"Coello C, Fisk M, Mohan D, Wilson FJ, Brown AP, Polkey MI, et al. Quantitative analysis of dynamic (18)F-FDG PET\/CT for measurement of lung inflammation. EJNMMI Res. 2017;7(1):47.","journal-title":"EJNMMI Res"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06820-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-024-06820-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06820-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:08:12Z","timestamp":1718878092000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-024-06820-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6820"],"URL":"https:\/\/doi.org\/10.1186\/s13104-024-06820-w","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with the declaration of Helsinki after approval by the Scientific Ethics Committee of The Region of Southern Denmark (j. no S-20170147) and Eudract (j. no. 2017-003551-32). The study was reported at clinicaltrials.gov (NCT03466021) and monitored according to Good Clinical Practice (GCP) by the GCP Unit of Odense University Hospital, Odense, Denmark. Informed consent was obtained from all individual participants included in the study","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CBJ serves as a speaker for Novo Nordisk, but has no financial interest in the current study. Study medication and running costs were provided by Novo Nordisk as a part of the Investigator Sponsored Studies Program. The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}